Background: Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for treating mild-tomoderate ulcerative colitis (UC). Unfortunately a significant group of patients fail to respond. Therapeutic drug monitoring might help to maintain or induce remission by providing a tool for optimization of 5-ASA therapy. However, plasma and urine concentrations of 5-ASA reflect systemic uptake and are not useful to evaluate therapeutic effect. Objectives: To explore if mucosal and faecal 5-ASA values correlate with disease activity and/or therapeutic effects in patients with inflammatory bowel disease, especially UC. Method: We identified studies that analysed 5-ASA in faeces or mucosa of humans using an oral 5-ASA formulation, using PubMed and Embase. Results: In total, 39 studies (n = 939) were included, 27 on faecal 5-ASA, 9 on mucosal concentrations, and 3 on both faecal and mucosal values. We included 33 cross-sectional studies, 3 randomised clinical trials, 2 longitudinal cohorts and 1 randomized cross-over study. Mucosal 5-ASA concentrations in healthy subjects and patients on equivalent doses of 5-ASA were not found to differ remarkably. In the sub-analysis of mucosal 5-ASA concentrations in patients with active or quiescent UC, a higher concentration was seen during remission. Faecal concentrations were associated with 5-ASA doses but not with disease activity. Differences in faecal or mucosal 5-ASA values could not be ascribed to different 5-ASA formulations. Conclusions: An increase of the mucosal 5-ASA concentrations was observed during remission in patients with UC. No clear relationship between the faecal 5-ASA excretion and the therapeutic efficacy was identified.
Introduction
Ulcerative colitis (UC) is a chronic relapsing disease, mainly affecting the large bowel and is characterized by contiguous mucosal inflammation. Literature reports prevalence rates ranging from 90.8 to 505.0 per 100,000 persons in Northern Europe [1] . Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for mild to moderate UC due to its effectiveness for both induction (RR 0.86, 95% CI 0.82-0.89) and maintenance of remission (RR 0.69, 95% CI 0.62-0.77) [2, 3] . In addition to its effectiveness, 5-ASA is a relatively nontoxic and moderately priced drug. Hence, 5-ASA is widely used in UC patients, up to 64% of Dutch UC patients are treated with 5-ASA [4] . Historically, oral 5-ASA has also been prescribed to patients with Crohn's disease (CD), but its efficacy has not been clearly proven [5] .
5-ASA exerts its anti-inflammatory effects locally on the colorectal mucosa. Mechanism of action includes downregulation and inhibition of many inflammatory pathways and enzymes such as cyclooxygenase, lipoxygenases, interleukin-1, tumour necrosis factor-α, mitogen activated protein kinase, nuclear factor-kB and p-21 activated kinase-1 [6] [7] [8] [9] . Also, induction of peroxisome proliferator-activated receptor γ and scavenging of free oxygen radicals have been implicated in the mechanism of action of 5-ASA [10, 11] .
Local metabolism of 5-ASA consists of acetylation to the inactive metabolite N-Acetyl-5-ASA by the N-acetyltransferase 1 enzyme in intestinal epithelial cells and by intraluminal bacteria. This acetylation process seems to be saturable [12, 13] . In the liver, N-acetyltransferase 1 metabolises systemically absorbed 5-ASA in a similar manner. 5-ASA is excreted as a mixture of free 5-ASA and N-Acetyl-5-ASA in both urine and faeces [14] .
Different Formulations
A variety of oral 5-ASA formulations are available on the market (online suppl. Table, see www.karger.com/ doi/10.1159/000499331). Since 5-ASA acts topically, all formulations aim to optimise drug delivery to the colonic mucosa with as little systemic absorption as possible [15] . To this end, prodrugs, pH-dependent release and time-dependent release formulations have been developed.
Therapeutic Drug Monitoring
Although all 5-ASA formulations have been proven to be effective for induction and maintenance of remission in UC, a significant subgroup of patients fails to respond.
Thirty-five per cent of the UC patients fail to reach (partial) remission after 8 weeks induction therapy with 5-ASA and 52% fail to maintain complete remission after 12 months maintenance therapy [16] . However, it is presently unclear whether these patients could benefit from a higher 5-ASA dosage [2, 3, 17] . It has been suggested that individual variations in local drug metabolism due to genetic polymorphism, or interactions with the patient's microbiome, explain different responses to 5-ASA [18, 19] . The currently available therapeutic options for non-responders include steroids, thiopurines and biologicals, which have more and potentially serious side-effects. In addition, the use of biologicals is associated with higher costs: biologicals are currently the main cost-drivers in the treatment of patients with inflammatory bowel disease (IBD) [4] . Tailoring 5-ASA therapy to the specific needs of patients by therapeutic drug monitoring (TDM) might therefore be a valid alternative strategy, and is already being applied for thiopurines and biologicals.
TDM comprises determination of drug concentrations in the individual patient with subsequent dose adaptation to improve the efficacy and/or safety or to assess drug adherence [20] . Most important before applying TDM, a clear relationship between the drug concentration and (un)wanted clinical effects has to be established [21] . In case of a clear concentration-effect relationship, TDM of oral 5-ASA could be used to evaluate the feasibility of dose intensification, where non-responders with sub-therapeutic concentrations could benefit from tailormade dose finding for treatment optimisation.
Several strategies have been employed to measure the concentration of 5-ASA [22] . The plasma and urine concentration reflect the fraction that is absorbed in the small intestine, which is not available for the topical effect on the colorectal mucosa. Therefore, plasma and urine concentrations can be used to evaluate systemic side effects but not for therapeutic effectiveness [23] [24] [25] . On the other hand, the concentration of 5-ASA in the colorectal mucosa or faeces represent local drug bioavailability at the side of action and in the gut lumen, respectively. Therefore, measurement of mucosal or faecal 5-ASA concentration might enable TDM in patients with UC.
A previous systematic review explored the pharmacokinetic profiles of oral 5-ASA formulations including urinary and faecal excretion [26] . In the present systematic review, we aim to explore whether the mucosal and/or faecal 5-ASA concentrations correlate with disease activity and/or therapeutic efficacy in patients with IBD, and thus have potential for TDM in UC patients. 
Materials and Methods
This systematic review was undertaken in line with the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement [27] . We registered our research protocol at PROSPERO with the following registration number CRD42018084816.
Search Strategy and Study Selection
We performed a systematic search of PubMed, MEDLINE and Embase databases from inception to January 11, 2018 using keywords relevant to "5-aminosalicylate" and "mucosal concentration" or "faecal concentration" (see Appendix 1 for all search terms). After discarding duplicates, 2 reviewers (M.M.M. and J.P.D.S.) independently screened titles and abstracts for inclusion, followed by full-text screening, using Covidence [28] . Discrepancies were discussed and resolved with a third reviewer (A.D.R.H.). Both reviewers screened reference lists and citations (by Scopus database) of the included studies for additional studies, so called "snowballing".
Inclusion criteria were as follows: 1. Healthy subjects (HS) and IBD (CD and/or UC) patients with an intact colon with the exception of a previous ileocecal resection with anastomosis.
2. Use of a regular oral 5-ASA formulation. "Regular" was defined as no self-designed 5-ASA formulations or uncoated oral 5-ASA. When an oral 5-ASA formulation was combined with topical 5-ASA administration, (part of) the study was not included.
3. Measurement of 5-ASA concentration (ng/mg or mmol/L), recovery of dose (%) or total amount (mg or mmol) in intestinal mucosa and/or faeces, faecal water or faecal dialysate. If only the total 5-ASA value (5-ASA plus N-Acetyl 5-ASA) was presented, the study was not included.
We included all (conference) abstracts and original studies, irrespective of design, setting, publication year, publication status restrictions or language.
Data Extraction and Assessment of Bias
The primary outcome of interest was the measured 5-ASA value. The most important variable was disease activity (if applicable), defined as active colorectal inflammation based on clinical, histologic or endoscopic findings.
The following data was extracted by one reviewer (M.M.M.) and checked by a second reviewer (J.P.D.S): characteristics of study (year, design, main research question), study population (number, UC or HS), disease activity (if applicable), oral 5-ASA formulation (dose, proprietary name), details regarding collection of faeces and mucosal samples (timing, biological material, biopsy site), and 5-ASA concentrations in faeces and/or mucosa. If values were solely presented in figures, Plot Digitizer was used for data extraction. Since oral 5-ASA efficacy has been established in UC patients only, we analysed UC and CD patients if possible separated. We used GraphPad to construct our figures [29] .
Two reviewers (M.M.M. and J.P.D.S.) critically appraised all included studies independently and any discrepancies were resolved by discussion with a third reviewer (A.D.R.H.). We developed our own critical appraisal tool because existing tools did not fit the design of the included studies and our research aim (legend detailed in Appendix 2). Figure 1 depicts the search results: 26 of 532 records were eligible. By snowballing we identified another 13 eligible studies [12, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . The 39 included studies (n = 939) included 3 conference abstracts [42] [43] [44] .
Results

Search Results and Study Characteristics
In total, 27 studies measured faecal 5-ASA concentrations (n = 437), 9 studies mucosal 5-ASA concentrations (n = 445) and 3 studies both faecal and mucosal concentrations (n = 57; Table 1 ). 5-ASA measurements were carried out in HS in 22 studies (n = 370), UC patients in 13 studies (n = 474), CD patients in 2 studies (n = 50) and both UC and CD patients (IBD) in 4 studies (n = 45). The different 5-ASA formulations investigated (number of studies in parenthesis) were: Asacol (19), Pentasa (17), Sulfasalazine (13), Olsalazine (11), Salofalk (3), Apriso (3), Lialda (3), Claversal (2) .
Critical Appraisal
Appendix 2 shows the full critical appraisal. In short, we appraised 8 studies of low (all faecal analysis) and 6 of high relevance. We considered 3 studies of low (all faecal analysis) and 17 studies of high validity. Only one study was appraised with both high relevance and high validity [37] .
We observed considerable clinical, methodological and statistical heterogeneity between studies that rendered meta-analysis not possible.
Mucosal Concentration
Disease and Activity Table 2 summarises the mucosal 5-ASA concentrations in HS and patients with UC and CD with active, quiescent or undefined disease activity. Because of the wide variability of 5-ASA concentrations, a clear distinction between HS and disease status could not be made solely based on 5-ASA concentrations.
Strikingly, several individual studies reported lower mucosal 5-ASA concentrations during inflammation. D'Inca et al. [44] found a significant lower mucosal 5-ASA concentration during the active state of UC, both based on endoscopic and histological criteria, compared to quiescent UC (endoscopic active state 35.7 ± 5.7 ng/mg vs. remission 60.1 ± 8.0 ng/mg, p = 0.02, and histologic active state 35.5 ± 5.6 ng/mg vs. remission 67.5 ± 9.2 ng/mg, p < 0.001) [45] . Naganuma et al. [46] detected an inverse correlation between the disease activity index of UC patients and mucosal van 5-ASA concentrations (r = 0.71, p < 0.001). This finding was confirmed by Frieri et al. [47] . In this study, mucosal 5-ASA cut-off levels were defined for the risk of recurrence in CD patients in whom an ileocecal resection had been performed: 80% recurrence rate at a colonic mucosal 5-ASA concentration < 20 ng/mg, 6% recurrence rate at a colonic mucosal 5-ASA concentration between 29 and 100 ng/mg and 0% recurrence rate at a colonic mucosal 5-ASA concentration higher than 100 ng/mg [48] . To put this into perspective, 28% of Asacol users showed a mucosal 5-ASA concentration of 70 ng/mg or higher [45] . Figure 2 shows a subgroup analysis of 4 studies which scored "+" for domain in our critical appraisal relevance criteria, that is, studies that compared patients with active UC to quiescent UC [44] [45] [46] [47] . Patients receiving 2-3 g/day of either Asacol, Pentasa or Sulfasalazine had higher mucosal 5-ASA concentrations during remission in each study. Vice versa, 5-ASA concentrations were found to drop during active disease as compared to quiescent disease in these studies.
Dose and Formulation
Hussain et al. [49] found a significant increase in the mucosal 5-ASA concentrations in HS with increasing doses of Asacol from 1.2 vs. 2.4 g/day (median 1.6 vs. 4.2 ng/mL; not shown in Table 2 because of different units) but not significant for 2.4 vs. 4.8 g/day [13] . However, in our overall analysis, mucosal 5-ASA concentrations did not clearly increase with an increasing dose of 5-ASA therapy (Table 2) .
A limited number of studies identified significant different mucosal 5-ASA values when using different formulations. D'Inca et al. [45] found higher mucosal 5-ASA concentrations using Asacol compared to Sulfasalazine and Pentasa and De Vos et al. [50] found lower mucosal 5-ASA concentrations after using azo-bonded prodrugs instead of time-and pH dependent release mesalazine compounds. Conversely, 2 other studies found higher mucosal concentrations of 5-ASA using the azo bonded pro-drug formula Olsalazine or Sulfasalazine as compared to Pentasa or Salofalk [46, 51] . Altogether, in our systematic analysis, we could not detect a clear difference of mucosal 5-ASA concentrations between the various oral 5-ASA formulations (Table 2) . Faecal Analysis Disease and Activity Figure 3 depicts the faecal 5-ASA values as concentration (Fig. 3a) , recovery of ingested dose (Fig. 3b ) and total amount (Fig. 3c ) of all multiple dose studies. The single dose studies (or study parts) analysed only HS and their results were comparable with multiple dose studies [12, 30, 31, 39, 42, 43, [52] [53] [54] .
Patients with active UC are only represented in Figure  3a : no difference in faecal 5-ASA concentration between HS and patients with active UC was observed. These results were comparable if we only included the multiple dose studies with a high validity. A, abstract only; c-o, cross-over; c-s, cross-sectional; CD, Crohn disease; HS, healthy subjects; IBD, inflammatory bowel disease (i.e., UC and CD patients mixed); RCT, randomized clinical trial; SD, single dose; UC, ulcerative colitis; 5-ASA, 5-aminosalicylic acid. corresponded with lower faecal 5-ASA recovery (Fig. 3b) . However, this relationship disappeared when only studies with high validity were included (data not shown).
Four studies compared faecal 5-ASA values in patients with active and quiescent UC or IBD. None found significant differences in faecal 5-ASA excretions based on disease activity [37, 40, 55, 56] . Figure 5 displays the results from 2 of these studies that provided quantitative data of faecal 5-ASA [37, 56] . Lower faecal 5-ASA concentrations during remission were found if patients were on low dose 5-ASA but not when UC patients used higher doses (Fig. 5a ). Figure 5b presents contradictory results: the faecal 5-ASA recovery decreases during remission in IBD patients using Asacol, Pentasa and Salofalk but not in patients using Olsalazine and Sulfasalazine.
Hussain et al. [13] found significantly higher faecal 5-ASA amounts by increasing Asacol from 1.2 to 2.4 g daily but a higher dose of 4.8 g daily did not significantly further increase faecal excretion. Lauritsen et al. [37] detected higher faecal 5-ASA concentrations for a higher dose of Olsalazine in patients with UC. In our systematic analysis, as shown in Figure 3a , a higher dose of oral 5-ASA correlates with a higher faecal concentration. This dose-concentration effect was even more evident if only high validity studies were included. However, this effect was less pronounced if faecal 5-ASA is expressed as recovery of ingested dose or total amount (Fig. 3b, c) .
Conflicting data was reported on faecal 5-ASA values in subjects using different formulations [32, 51, [56] [57] [58] . We could not find a clear effect of formulation on faecal 5-ASA excretion (Fig. 3) .
Discussion
In this review, we found a clear inverse relationship between UC disease activity and mucosal 5-ASA concentrations but not with faecal 5-ASA concentrations after oral intake of 5-ASA formulations.
Our finding that an increase in mucosal concentration is associated with quiescent disease is in line with studies that compare oral versus oral plus topical (combination) 5-ASA therapy. Placebo controlled trials showed that combination therapy is more effective than oral therapy alone [59] , and pharmacokinetic studies established higher mucosal concentrations during combination therapy than during oral therapy alone [33, 45, 46, 60, 61] . Frieri et al. [33] analysed both mucosal concentrations and therapeutic efficacy in UC patients using oral therapy versus combination therapy. They conclude that combination therapy leads to higher mucosal concentrations plus less flares, less steroid use, less endoscopies needed and less hospitalisation. These findings strengthen our conclusion that higher mucosal concentrations are associated with less disease activity and thus higher therapeutic efficacy.
We have focused this review on the measurement of 5-ASA concentrations. N-Acetyl-5-ASA has also been measured in several studies, but this is an inactive metabolite. This metabolite has been used to evaluate the release characteristics of the 5-ASA formulation, as it is an indicator of timely (proximal) release of 5-ASA in to the gut lumen, but N-Acetyl 5-ASA is not considered a relevant biomarker for evaluating therapeutic efficacy [52, 56, 62] .
Heterogeneity
The aforementioned inverse relationship between UC disease activity and mucosal 5-ASA concentrations was conclusive only when studies with a clinical relevant domain were analysed, that is, UC patients with active disease compared to patients in remission in individual studies (Fig. 2) . Several factors contributing to the heterogeneity of included studies may explain the absence of a relationship between disease activity and the mucosal 5-ASA concentration when all studies were included in the analysis (Table 2) . First and foremost, mucosal 5-ASA concentrations have a high intrasubject variability (intrasubject coefficient of variation: 54%, range 0-173%) [34] . Second, the mucosal 5-ASA concentration is significantly lower after mucosal washing before biopsy, but whether mucosal washing was performed was not always specified in the included studies [34] . Third, the site of biopsy may affect the outcome. Although De Vos et al. [63] found no ileum-colon concentration gradient in the steady-state intramucosal concentration for several oral 5-ASA formulations in HS, Frieri et al. [60] showed higher mucosal 5-ASA concentrations at the proximal site of the intestine compared to the distal site in CD patients using Asacol. Hence, we depicted the location of biopsy taking in Table 2 . Fourth, although all mucosal 5-ASA concentrations were determined with high-pressure liquid chromatography, differences in preparation and measurements may have hindered comparison of study outcomes. For example, in some studies 5-ASA concentrations were measured directly after biopsy while others stored the biopsies for different durations at -80 ° C. Another essential point relates to the different included phenotypes of IBD. For instance, Frieri et al. [48] included CD patients with terminal ileum resection and ileocolonic anastomosis, as opposed to all other studies in Table 2 [64] . Since in daily clinical practice oral 5-ASA is prescribed to CD patients as well, we did not exclude CD patients. To minimize bias, we analysed data separately for each type of IBD. Finally, the last factor contributing to heterogeneity is that disease activity of UC or CD patients listed in Table 2 was either based on clinical, endoscopic or histological findings. In addition, studies used different criteria for clinical, endoscopic or histological remission.
In line with studies focussing on mucosal 5-ASA concentrations, studies exploring the faecal 5-ASA concentrations show considerable heterogeneity as well, thereby precluding to draw definite conclusions on the association of faecal 5-ASA concentrations and disease activity. First, the use of different criteria to score disease activity might have affected the overall results. Second, there were remarkable differences between included subjects. Four studies did not distinguish CD and UC patients but analysed patients as one group ("IBD") [30, 35, 38, 56] . Also, in one study, children were included as well [65] . The recovery of ingested dose was significantly lower in children compared to adults, which may have influenced the overall results of our analysis. Another example is the duration of oral 5-ASA ingestion, which varied between patients or subjects from one single dose (excluded from Fig. 3 ), to several days or weeks. Third, some studies determined the faecal concentration in a dialysate bag instead of the faeces itself [32, 37, 41, 51, 55] . Faeces consist of free faecal water plus solid fibrous or bacterial components [32] . Higher concentration of 5-ASA in faeces than in a free faecal water concentration from a dialysate bag can be detected due to the solid fibrous and bacterial components that may bind salicylates [40] . Fourth, when interpreting the results of total amount of faecal 5-ASA, it should be taken into account that the collection time of faeces varied per study from 24 to 240 h (Table 1) . To adjust for this variability, the total amount of faecal 5-ASA is expressed per 24 h (Fig. 3c) . Finally, differences in sample pre-treatment, required to prevent degradation of 5-ASA by oxidation and further acetylation by bacterial flora, might have affected the outcomes and hampered thereby a comparison between studies. The stability of faecal compounds is uncertain [66] . Most studies used methanol as storage medium, whereas other studies used methanol plus a phosphate buffer [13, 31, 34, 35, 39, 49, 55, 57, 67] or HgCl 2 [31, 36] . Of note, food intake of subjects has been shown to not influence faecal 5-ASA concentration [53] .
Clinical Implications
Mucosal 5-ASA concentrations may be affected by several patient characteristics during colonic inflammation, such as intestinal transit time. Two studies compared the faecal 5-ASA concentration in HS between normal transit time and accelerated transit time, employing bisacodyl-induced diarrhoea. Both studies reported an increased faecal recovery of the ingested 5-ASA dose during accelerated transit time compared to normal transit time (median 29%, range 16-38% vs. 16%, 9-21%) [52, 67] . In theory, a higher faecal concentration during diarrhoea corresponds to a lower mucosal concentration and thus decreased efficacy, although this relationship has not been clearly established: only 3 studies analysed both faecal and mucosal 5-ASA concentrations, but none of them compared these concentrations in patients with and without diarrhoea/inflammation [13, 34, 38, 49] .
In addition to intestinal transit time, intraluminal pH is often decreased during active inflammation, which may influence the release of 5-ASA from its formulation and thereby influence the mucosal 5-ASA concentration [13, 68] . Further, relevant enzymes and transporters responsible for colonic 5-ASA metabolism and apical secretion back into the colonic lumen may alter during inflammation [14] . On top of that, low mucosal 5-ASA concentrations during active disease might result from a dilution effect secondary to cell oedema. Alternatively, low mucosal 5-ASA concentrations during inflammation may reflect the influence of active lesions, such as ulcers, with increased permeability due to alterations in tight junctions and local leaks, plus a secondary loss of mucosal absorption ability [46, 69] . Another hypothesis is a faster rate of tissue renewal in the presence of inflammation, establishing a washout effect [45] . In this case, a higher mucosal concentration during remission reflects the decreased epithelial cell turnover compared to the healing phase [70] .
If colonic inflammation directly leads to a lower mucosal 5-ASA concentration, this can be considered biomarkers for disease activity rather than a tool for TDM. Preferably, a large longitudinal prospective cohort study should be performed to establish a potential causal relationship and the sequence in which events take place (active inflammation resulting in a decrease in mucosal 5-ASA concentration or vice versa).
Limitations
The fact that a part of the included studies was pharmacokinetic studies presenting 5-ASA levels, hence not (primarily) designed to relate 5-ASA levels with disease activity and/or therapeutic efficacy, hampers the interpretation of our results.
Furthermore, although we found a relationship between mucosal concentration and disease activity, this does not necessarily imply that measuring 5-ASA levels will lead to optimisation of 5-ASA dosing and thus improve clinical efficacy in UC patients. Our study could be a starting point for further research investigating TDM of 5-ASA, as it is the first systematic review exploring this topic.
Conclusion
Theoretically, TDM of oral 5-ASA may enable individual dose finding where non-responders with sub-therapeutic concentrations could benefit from dose intensification rather than step up therapy. Optimization of oral 5-ASA therapy would be preferable because it is a relatively safe drug and non-expensive compared to biologicals. However as a first step, a clear concentration-effect relationship has to be established before personalized therapy could be an opportunity. In this systematic review, we found that the mucosal 5-ASA concentration may offer a tool for tailoring therapy in UC patients: an increase in the mucosal concentration is associated with remission. It may be speculated that lower mucosal 5-ASA concentrations during maintenance therapy may predispose patients to relapse. Due to the large heterogeneity of studies, a universal threshold concentration could not be identified. Unfortunately assessment of mucosal concentrations is invasive and not always feasible. The assessment of faecal 5-ASA excretion would be an attractive van alternative if an excretion-effect relationship could be established clearly. Although there is a relationship between the given oral 5-ASA dose and the faecal concentration, no faecal 5-ASA concentration -therapeutic effect relationship has been established yet. Ideally, both the faecal and mucosal concentration-effect relationship of oral 5-ASA in UC patients with active and quiescent disease activity should be established in a single study.
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